ARVINDREM

Arvind Remedies Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on August 12, 2016, decided to defer all other items, intimated vide Company's letter dated August 02, 2016 to the next meeting.

Arvind Remedies Limited has informed the Exchange that the Board Meeting held on November 26, 2015 has discussed in detail reasons for the delay, the financial constraints through which the company is passing through, and the restructuring request with the banks through investor by SDR route for which negotiations are going on. Board felt that instead of considering unaudited results for the quarters ended March 31, 2015 and June 30, 2015 to avoid the notice of suspension, since the audit is going on, it is advisable to come out with the audited results for these quarters, along with the unaud

Arvind Remedies Limited has informed the Exchange that in the Board Meeting held on July 11, 2015, the following decisions were taken.(1). Board approved the investment proposal presented by M/s. Global Allied Pharmaceuticals LLc, including product development. It was decided to enter into agreement stating in detail the amount to be invested and the terms and conditions and the same be placed for approval of the shareholders.(2). Considering the proposed investment, it was decided to increase the authorised share capital of the company accordingly.(3). It was decided to appoint Dr. Timothy Al

Arvind Remedies Limited has informed the Exchange regarding outcome of meeting of the Board of Directors of the Company held on May 28, 2015.

Arvind Remedies Limited has informed the Exchange that the Board of Directors at its meeting held on February 27, 2015 has discussed on the status of strike by workers, the conciliation efforts, and the decision pending at Court. It was informed that due to strike and resultant improper humidity & environment conditions, damage has been caused to the goods in process and thereby there is loss in the current quarter. Board discussed on the debt restructuring proposal which has been taken up in view of the liquidity problem. It was felt that restructuring will be beneficial to the Company, and d

Arvind Remedies Limited has informed the Exchange that in the meeting of Board of Director held on February 11, 2015, the following decisions were taken . 1. Due to issue of further equity shares by Coronet Labs P Ltd, (CLPL) the subsidiary Company, the shareholding of the Company in CLPL reduced substantially and CLPL ceased to be subsidiary. It was decided that this information be given by way of note below the financial results for the quarter ended December 31, 2014. 2. It was decided that in the next Board Meeting convened on February 27, 2015, the Corporate Restructuring proposal with

Arvind Remedies Limited has informed the Exchange that the Board of Directors held on August 09, 2014, following decisions were taken (1)The status of demerger petition filed in High Court, Chennai was discussed. Board felt that considering the changed scenario and for the reasons external to the company, it is advisable not to pursue with the scheme. Accordingly it was decided to withdraw the petition from the High Court. (2).That the shareholders approval for the borrowing powers pursuant to the Companies Act 2013 be taken by e-voting before September 11, 2014.

Arvind Remedies Limited had informed the Exchange that the meeting of the Board of Directors of the Company is scheduled to be held on May 06, 2014 to consider and take on record the audited financial results of the company for the quarter and year ended March 31, 2014 and to recommend dividend if any on the equity shares of the company. The Company has now informed the Exchange that due to unavoidable circumstances, the above meeting is postponed.

Arvind Remedies Limited has informed the Exchange that the Board of Directors of the Company at its meeting held on May 15, 2013 has taken the following decisions : (1). Board approved the Demerger of Irungattukottai Unit of the Company into their Wholly Owned Subsidiary (WOS), Arvind Wellness Limited and fixed the appointed date as April 08, 2013. It was noted that the resultant Company (WOS) will be issuing preference share to the shareholders of ARL as a part of the demerger scheme. For the above purpose, the Board authorised Dr. B. Arvind Shah, Managing Director to sign, execute and file n

Arvind Remedies Limited has informed the Exchange that in the Board meeting held on November 08, 2012 the Board has discussed and decided that the Company has plans to get registered its Irungatukottai unit as USFDA project. Company has received offer from M/s. Vensun Pharmaceuticals LLc in US for marketing tie up and for development of products with USFDA registration in the new plant at Irungatukottai, Dist. Kancheepuram Tamil Nadu and for supply to that country. Board authorized Managing Director to sign the MOU with the said company and to finalise the terms and conditions in this regard.